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ZNF165 is a zinc-finger protein gene that was identified from human adult testis. Analysis of the origins of publicly available expressed
sequence tags as presented in Unigene and SAGE databases revealed that ZNF165 mRNA was expressed in tumours of different
tissues. RT–PCR, real-time PCR and Northern blotting analysis confirmed that ZNF165 mRNA was expressed in the hepatocellular
carcinoma, gastric cancer, colon cancer and non-small-cell lung carcinoma. The nucleotide sequence of ZNF165 expressed in
tumours is identical to that expressed in the testis. Humoral responses of hepatocellular carcinoma (HCC) patients against ZNF165
protein were determined by Western blotting using the recombinant ZNF165 protein. Antibodies against ZNF165 protein were
detected in approximately 5% (four of 82) of the sera from HCC patients. These results suggest that ZNF165, a member of the ZNF
family, is a novel CT antigen capable of eliciting humoral immune response and be involved in tumour biology.
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Tumour development is a result of multiple genetic alterations.
Tumour cell phenotype has six hallmarks: disregarding signals for
growth arrest; failure to differentiate; capacity of sustained
proliferation; evasion of apoptosis; ability of invasion; and
enhanced angiogenesis (Bishop, 1987; Compagni and Christofori,
2000). A major challenge in tumour research is to illustrate how
these phenotypic alterations result in tumorigenesis. Genes
involved in promoting cellular proliferation are often altered in
tumours; however, the mechanisms underlying the alternations are
poorly understood. Many of these genes encode transcription
factors that are the principal modulators of gene expression in the
organism. Zinc-finger family of proteins is one of the most
common families of transcription factors in eukaryotic cells and
has more than 3000 members in the human genome. They are
known to play a key role in regulating expression of genes
important for cell growth, proliferation, differentiation and
apoptosis (Cox and Goding, 1991; Papavassiliou, 1995; Ladomery
and Dellaire, 2002). Owing to their multiple functions, some zinc-
finger proteins are powerful regulators in the development of the
tumour. For example, WT1 has been demonstrated to be
responsible for the development of Wilm’s tumour (Lee and
Haber, 2001). The other well-characterised examples of zinc-finger
proteins involved in tumorigenesis include those encoded by the
genes of GLI, KS1, Evi9 and BCL11 subfamilies. However, the role
of remainder members of the zinc-finger family in tumour
development is not clear as yet (Dunaeva et al, 2003; Liu et al,
2003; Mitas et al, 2003). Therefore, investigation of additional zinc-
finger proteins associated with tumorigenesis may provide insight
into molecular mechanisms underlying tumorigenesis.
Hepatocellular carcinoma (HCC) is one of the most common
and severe malignancies worldwide and its therapeutic results
remain unsatisfactory. The identification of cancer-testis (CT)
antigens recognised by cellular and/or humoral effectors of the
immune system has provided new perspectives for HCC immu-
notherapy (Knuth et al, 2000). However, a crucial factor alleviating
the efficacy of the immunotherapy is the immunoselection
developed during the period of vaccine application and resulted
in the progressive loss of tumour antigens (Giorgio et al, 2002). To
improve the efficacy of tumour vaccines and decline immune
escape, further identification of novel CT antigens is warranted for
the development of applicable polyvalent tumour vaccines.
ZNF165, expressed in human adult testis, is a member of
kruppel family of zinc-finger-containing transcription factors
(Tirosvoutis et al, 1995). In this report, we have examined
ZNF165 mRNA expression in tumours of different histological types
using various approaches. We have found that ZNF165 mRNA is
also expressed in the hepatocellular carcinoma, gastric cancer,
colon cancer and non-small-cell lung carcinoma. Furthermore,
antibodies against ZNF165 protein have been detected in the sera of
some HCC patients. Thus, ZNF165 is a novel member of CT antigen
family and may be both immunogenic and tumorigenic in HCC.
MATERIALS AND METHODS
Human tumour tissues
All samples of human HCC, gastric, colon and non-small-cell lung
cancers and paired noncancerous tissue (5cm away from tumour)
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ywere obtained during surgical resection from the 2nd Teaching
Hospital, Peking University Health Science Center, China. Tissue
samples were collected with patients’ written consent and
approved by Hospital Ethic Review Committee. The resected
tissue samples were immediately cut into small pieces and snap
frozen in liquid nitrogen until use. All tumour and paired
noncancerous tissue samples were pathologically confirmed. The
clinical stage of HCC patients was assessed according to the TNM
classification of the International Union Against Cancer, and the
histopathological grade of HCC differentiation was assessed
according to the Edmondson Grading System. The patients from
whom the resected HCC samples were obtained were HBV surface
antigen positive but HCV antigen negative.
RT–PCR
The mRNA expression pattern was determined using RT–PCR
with a panel of commercially available cDNAs (Clontech, Palo
Alto, CA, USA). The panel is composed of cDNAs generated from
RNA isolated from 16 normal tissues: brain, heart, kidney, liver,
lung, pancreas, placenta, skeletal muscle, colon, ovary, peripheral
blood leucocyte, prostate, small intestine, spleen testis and thymus.
RNA from human HCC, gastric, colon and non-small-cell lung
cancers and paired noncancerous tissues was extracted and reverse
transcribed with Advantage reverse transcriptase (Clontech, Palo
Alto, CA, USA). Gene-specific PCR primers were used to amplify
cDNA fragments of ZNF165. RT–PCR was performed with the
parameters as follows: 30 cycles, 941C, 15s; 601C, 30s; and 721C,
30s, followed by 6min at 721C. Visualisation of target bands on a
1.2% agarose gel with ethidium bromide staining was performed to
determine the expression of ZNF165 mRNA in the different types
of tissues. The sequences of paired primers for the amplification of
ZNF165 are: forward, ccc aga gag tgg aga gga ggc ag; and reverse,
aac ctt cat cct ggg cag acg ag. To investigate if ZNF165 mRNA
expressed in tumours is identical to that in the testis, a pair of
primers spanning the open reading frame (ORF) of ZNF165 was
designed and RT–PCR was performed using the template cDNAs
from tumours and testis, respectively. The PCR amplification
parameters were as follows: 30 cycles, 941C, 15s; 581C, 30s; and
721C, 1.5min, followed by 6min at 721C and the sequences of the
primers: forward, caa gat ggc tac aga acc aaa gaa agc; and reverse,
cat att gtg cca ttt cct cag cat tta c. The PCR products from tumours
and testis were cloned and sequenced, respectively.
Quantification of gene expression
Quantification of ZNF165 mRNA expression was performed by
monitoring the increase in fluorescence by the binding of SYBR
green to double-stranded DNA during real-time PCR. Their
specific amplification primers were those described above. All
reactions were carried out in triplicate with positive and negative
controls using the standard program (the iCycler iQ Real-Time
PCR Detection System, Bio-Rad Laboratories, California, USA).
Melt-curve analysis was performed to determine the temperature
at which data were collected. To collect data in real-time PCR,
reaction mixtures were incubated at 501C for 2min and then 951C
for 10min prior to 40 cycles of PCR (951C for 15s, 601C for 30s,
721C for 30s and 881C for 10s). Serial 1:10 dilutions of plasmid
DNA containing ZNF165 cDNA (10
4,1 0
5,1 0
6,1 0
7,1 0
8 and 10
9
copiestube
 1) were analysed and served as the standard curve.
Copy number of ZNF165 cDNA was estimated by the standard
curve. The specificity of PCR amplifications was confirmed by
electrophoresis on a 1.2% agarose/EB gel. To determine the mRNA
level of ZNF165, we used an mRNA EI, which indicates a relative
level of mRNA expression standardised by G3PDH. The mRNA EI
was calculated as following (in AU): mRNA EI¼(copy number of
ZNF165 mRNA/copy number of G3PDH mRNA) 1000AU.
Northern blot analysis
Northern blotting was performed with mRNA samples extracted
from HCC and paired noncancerous liver tissues. RNA integrity
was examined by electrophoresis in formalin/4-morpholine
propane sulphonic acid gels. In all, 10mg of mRNA per lane were
first separated by electrophoresis in 1.2% agarose containing 3%
formaldehyde and then blotted onto Hybond-C nylon membranes
(Amersham). The membrane was crosslinked by ultraviolet
radiation. The DIG-labelled probes were the cDNA sequence of
ZNF165 (425bp). After prehybridisation, the membrane was
hybridised to specific DIG-labelled probes overnight at 421Ci n
hybridisation solution (50% formamide, 5 SSC, 0.1% N-laur-
oylsarcosine, 0.02% SDS, 2% Blocking reagent and 100mgml
 1
sheared salmon sperm DNA). Filter was then sequentially washed
at room temperature for 30min in 0.1% SDS and 2 SDS, and at
681C for 30min in 0.1% SDS and 0.1 SDS. After stringent washes,
the corresponding mRNA in Northern blotting was detected by
chemiluminescence using CSPD ready-to-use reagent (Roche,
Indianapolis, USA).
Expression and purification of ZNF165 recombinant
protein in Escherichia coli
Expression construct of ZNF165 was created by PCR amplification
of the full-length cDNA with the 50 and 30 primers: gcg gga tcc atg
gct aca gaa cca aag aaa gc and gcg gtc gac tgc cat ttc ctc agc att tac.
The amplified products were digested with BamHI and SalI, and
the fragment was inserted into the expression plasmid pET28a
(þ) followed by DNA sequencing. The recombinant plasmid
pET28a/ZNF165 was transformed into E. coli BL-21 and the
recombinant ZNF165 protein accounted for 15% of total protein.
After the induction with 1mM IPTG at 371C for 6h, the
recombinant ZNF165 protein fused with 6 His tag was purified
by Ni
2þ affinity chromatography.
Western blotting
Purified recombinant ZNF165 protein was separated on 10% SDS–
polyacrylamide gel electrophoresis and transferred onto nitrocel-
lulose membranes. After blocking with the TNT solution contain-
ing 5% dry milk, the membranes were incubated with sera from
normal individuals or HCC patients at a 1:500 dilution for 1.5h,
and then with goat anti-human IgG (HþL) alkaline phosphatase
conjugate (Promega) for 1h. Colour substrate NBT/BCIP (Prome-
ga) was added and incubated for 10min for colour development.
RESULTS
Databases analysis
Unigene is an experimental processing system for automatically
partitioning GenBank sequences into a nonredundant set of gene-
oriented clusters. Each Unigene cluster contains sequences that
represent a Unigene, as well as the related information such as the
tissue types in which the gene is expressed. The Unigene
incorporates hundreds of thousands of sequences of expressed
sequence tag (EST) whose tissue distributions are labelled
(Schuler, 1997). SAGE is an on-line technique that allows
quantitation and comprehension of cellular gene expression
profiling (Velculescu et al, 1995). Consequently, Unigene and
SAGE can be used to analyse the spatial and temporal expression
pattern of a given gene and predict the functional information of
the gene. In the database of Unigene, there were 25 ESTs
representing ZNF165. Although 14 of these ESTs were identified
in the libraries of normal tissues such as the testis and placenta
(10), pancreatic islet (3) and breast (1), the remainder 11 ESTs
were derived from several types of tumours, such as uterus
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ytumour, well-differentiated endometrial adenocarcinoma, leiomyo-
sarcoma, germ cell tumour and carcinoid. In the SAGE database,
one tag (AGGGAAAACC) representing ZNF165 was identified
from the libraries of mammary gland carcinoma, prostate
carcinoma and pancreas adenocarcinoma, respectively. These data
suggest that ZNF165 mRNA has the expression characteristics
typical of a CT antigen gene.
Expression profile of ZNF165 mRNA
One of the criteria for identifying CT antigen genes is their specific
expression in tumours, but not in normal tissues except the testis.
The mRNA expression profile of ZNF165 was determined by RT–
PCR. A series of tissues were examined, including normal tissues,
HCC, gastric, colon and non-small-cell lung cancers and paired
noncancerous tissues.
mRNA expression of ZNF165 was first examined by RT–PCR
with the amplification by 30 cycles in 16 different normal tissues
including the spleen, prostate, testis, ovary, small intestine,
colon, peripheral blood, heart, lung, liver, whole brain, kidney,
pancreas, placenta, thymus and skeletal muscle. ZNF165 mRNA
expression was detected only in the testis (Figure 1A). However,
quantification of gene expression by real-time PCR with the
amplification of 40 cycles revealed that ZNF165 mRNA could
also be detected in the placenta, lung, liver, pancreas, spleen,
thymus and colon, but not in other tissues. The average EI
values of ZNF165 mRNA expression in the testis and other
normal tissues including the placenta, lung, liver, pancreas,
spleen, thymus and colon are 33.56 and 0.24, respectively.
Therefore, the expression level of ZNF165 mRNA in these
normal tissues was 140-fold lower than that in the testis
(Figure 2).
We then analysed ZNF165 mRNA expression in HCC and paired
noncancerous liver tissues. The ZNF165 mRNA transcript was
present in 22 of 42 HCC samples (52%) and eight of 42 paired
noncancerous liver tissues. Representatives of such analyses are
shown in Figure 1B. The average quantification of ZNF165 mRNA
was 88-fold higher in HCC (the average EI value is 22.81 in 22
samples of ZNF165 mRNA positive) than in paired noncancerous
liver tissues (the average EI value is 0.26 in eight samples of
ZNF165 mRNA positive) (Figure 2). Of the 22 HCC samples of
ZNF165 mRNA positive, there were 5, 6 and 11 samples belonging
to well, moderate and poor differentiation status, respectively;
there were 6, 8 and 8 samples belonging to clinic I–II, III and IV,
respectively. Although the higher percentage of ZNF165 mRNA
expression was observed in HCC patients with poor differentiation
status, there was no correlation of the expression of ZNF165
mRNA with the clinic stage and tumour differentiation status of
HCC patients (P40.05).
To assess whether ZNF165 mRNA was expressed in tumours of
different histological types, their mRNA levels in the gastric,
colon and non-small-cell lung cancer tissues were tested. ZNF165
mRNA was expressed in six of 14 gastric cancer samples (43%),
six of 14 colon cancer samples (43%) and in three of 14 non-
small-cell lung cancer samples (21%). Thus, ZNF165 mRNA was
expressed in tumours of various histological types and normal
testis. Sequencing results of RT–PCR products showed that the
nucleotide sequence of ZNF165 expressed in tumours was also
identical to that expressed in the testis. Therefore, there was no
mutation in the ORF sequence of ZNF165 expressed in tumours
(data not shown).
Seroreactivity of antibodies against ZNF165 protein in the
sera of HCC patients
A survey of the humoral immune response against ZNF165 antigen
in HCC patients was performed by Western blotting. Of the 82 sera
collected from HCC patients, four sera were reactive to ZNF165
protein (Figure 3). Noticeably, although the expression of ZNF165
mRNA was not correlated with the clinic stage and tumour
differentiation status of HCC patients, all the four seroreactive
HCC patients were in the poorly differentiated status of clinic II
(one of four), III (one of four) and IV (two of four) stage,
respectively. As controls, in the 36 sera collected from normal
individuals, none was reactive to ZNF165 protein (Figure 3).
Moreover, sera collected from HCC, whose resected tumour tissue
samples did not express ZNF165 mRNA, were serologically
negative to ZNF165 protein.
8 7 6 5 4 3 2 1
16 15 14 13 12 11 10 9
N Ca N Ca N Ca N Ca
ZNF165
ZNF165
ZNF165
G3PDH
A
B
Figure 1 Expression patterns of ZNF165 mRNA in 16 normal tissues,
HCC and paired noncancerous liver tissues. (A) Gel electrophoresis of
RT–PCR products amplified by 30 cycles shows ZNF165 mRNA
expression in 16 normal tissues. ZNF165 mRNA is only expressed in
testis. 1–16 normal tissues: 1. brain; 2. heart; 3. kidney; 4. liver; 5. lung; 6.
pancreas; 7. placenta; 8. skeletal muscle; 9. prostate; 10. ovary; 11.
leucocyte; 12. testis; 13. small intestine; 14. spleen; 15. colon; 16. thymus.
(B) Gel electrophoresis of RT–PCR products amplified by 30 cycles shows
ZNF165 mRNA in the paired HCC and noncancerous liver tissue samples.
RT–PCR for G3PDH was used to monitor the quality of the mRNA
samples. Ca: HCC; N: paired noncancerous liver tissues.
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Figure 2 Quantification of ZNF165 mRNA expression in 22 HCC
tissues, eight noncancerous liver tissues and normal tissues including the
testis, placenta, lung, liver, pancreas, spleen, thymus and colon. Hepatocel-
lular carcinoma: the average EI value is 22.81 in 22 HCC samples of
ZNF165 mRNA positive; noncancerous liver tissues: the average EI value is
0.26 in eight noncancerous liver samples of ZNF165 mRNA positive; testis:
the EI value is 33.56 in the testis; normal tissues: the average EI value is 0.24
in normal tissues including the placenta, lung, liver, pancreas, spleen, thymus
and colon in which ZNF165 mRNA was expressed.
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yDISCUSSION
In this study, we have demonstrated that ZNF165, a gene identified
from adult testis, is a novel CT antigen gene. The mRNA
expression of ZNF165 has been found in human HCC, gastric,
colon and non-small-cell lung cancers.
Examination of ZNF165 mRNA expression pattern by RT–PCR
with 30 cycles revealed that ZNF165 was not detected in normal
tissues except the testis. Under real-time PCR, the ZNF165 mRNA
was not only expressed in tumours and normal testis but also
could be detected in paired noncancerous tissues and some normal
tissues including the placenta, lung, liver, pancreas, spleen, thymus
and colon. Considering that some CT antigen genes like NY-ESO-1
and MAGE-A3 are reported to be detected in normal tissues
(Scanlan et al, 2002) and we have also confirmed that NY-ESO-1
mRNA was detected in normal liver tissues by real-time PCR, our
data support that ZNF165 is a novel CT antigen. Like most of the
other CT antigens capable of inducing the humoral immune
response and the cellular immune response in a minor proportion
and a considerable proportion of cancer patients, respectively
(Jager et al, 2001; Kirkin et al, 2002), the ZNF165 antigen
spontaneously elicited antibody response detected in approxi-
mately 5% of HCC patients. There was no serological reactivity
detected in the sera of healthy blood donors. Since the majority of
ZNF165 antibodies detected are of the IgG class, the activation of
CD4
þ T-cell response to ZNF165 antigen could be present
(Kennedy et al, 2003). Further experiments are ongoing to test if
the ZNF protein could provoke cytotoxic T-cell response in cancer
patients.
The results of Northern blotting further confirmed that ZNF165
mRNA was expressed in tumours (data not shown). ZNF165
mRNA detected in tumours is 2.2kb, consistent with that found in
the testis (Tirosvoutis et al, 1995). The ORF of ZNF165 cDNA
encodes a predicted protein of 485 amino-acid residues. This
protein has an N-terminal acidic domain containing 17% aspartic
and glutamic acid residues and a C-terminal domain with five
conserved C2H2-type zinc-finger motifs. ZNF165 is predicted to be
a nuclear protein with an isoelectric point of 7.0. There were three
N-myristoylation sites, one N-glycosylation site and several kinase
phosphorylation sites. Thus, ZNF165 may undergo post-transla-
tional modifications. By comparing the cDNAs to the human
genome, ZNF165 gene was located to chromosome 6p21.3, where a
cluster of zinc-finger family members is located, such as ZNF184
and ZNF345. Members of this DNA-binding protein family act as
transcriptional regulators.
Apart from a few zinc-finger proteins, such as WT1, BCL11A,
Evi9, EWS, TLS, GLI, and CTCF, the function of the majority of
zinc-finger proteins in tumour occurrence and development is
unknown (Lee and Haber, 2001; Klenova et al, 2002; Liu et al, 2003;
Dunaeva et al, 2003; Shing et al, 2003; Zwerner et al, 2003). As a
zinc-finger protein containing an N-terminal acidic domain and a
C-terminal domain with five conserved C2H2-type zinc-finger
motifs, the ZNF165 may function in the transcriptional regulation.
Transcription factors are the principal modulators of gene
expression in the normal tissue development as well as in
tumorigenesis once their function or expression pattern is altered.
It remains to be determined whether the expression of ZNF165 is
involved in tumorigenesis and progression. Answers to these
questions will help to further understand tumour formation.
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